New Stock News | Jingyin Pharmaceutical submits second filling to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on March 31st, Jingyin Pharmaceutical (also known as Sirius Therapeutics) submitted its listing application to the main board of the Hong Kong Stock Exchange with Goldman Sachs, Haitong International, and HSBC as its joint sponsors. This is the company's second listing application to the Hong Kong Stock Exchange. The prospectus shows that Jingyin Pharmaceutical is a global clinical-stage biotechnology company founded in 2021, focusing on siRNA therapy for coagulation disorders, cardiovascular and metabolic diseases, and obesity.